ArticlePloS one2018

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.

Franck Maunoury et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.